493
Articles
35.2K
Citations
4
avg. Impact Factor
90
h-index

Most Cited Articles of Discovery Medicine and Clinical Pharmacology in 2017

TitleJournalYearCitations
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trialLancet Diabetes and Endocrinology,the2017174
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future ApplicationsClinical Cancer Research201751
Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung CancerClinical Cancer Research201748
PD-1 blockade enhances elotuzumab efficacy in mouse tumor modelsBlood Advances201732
Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomesAnnals of Oncology201731
Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective studyRMD Open201730
Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of RosuvastatinDrug Metabolism and Disposition201728
Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic ModelJournal of the American Society of Nephrology: JASN201727
Na channel variants in patients with painful and nonpainful peripheral neuropathyNeurology: Genetics201725
High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney diseaseKidney International201723
Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRDBMJ Open201723
Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in GermanyPLoS ONE201722
Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI aloneAnnals of Oncology201722
Duplicated Enhancer Region Increases Expression of CTSB and Segregates with Keratolytic Winter Erythema in South African and Norwegian FamiliesAmerican Journal of Human Genetics201719
Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational studyRMD Open201716
Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or WarfarinStroke201713
Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug ResponseCPT: Pharmacometrics and Systems Pharmacology201710
Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotypeCurrent Medical Research and Opinion20177
Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation: Assessment via a Large Insurance DatabaseStroke20177
Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trialLupus Science and Medicine20177
Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)Annals of Oncology20176
IFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)Annals of Oncology20175
Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimodAnnals of Oncology20173
EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL)European Journal of Cancer20172